Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 40

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 40
---
 an approximation of grant date fair value), total target cash compensation (base salary and the annual target performance bonus) and total direct compensation (total target cash compensation and equity compensation) with respect to each of the named executive officers. The Compensation Committee did not target pay to fall at any particular percentile of the market data, but rather reviewed these market data reference points as a helpful reference point in making 2024 compensation decisions. Market data is only one of the factors that the Compensation Committee considers in making compensation decisions. The Compensation Committee considers other factors as described under the section titled “— Factors Used in Determining Executive Compensation .”

Factors Used in Determining Executive Compensation

Our Compensation Committee sets the compensation of our executive officers at levels they determine to be competitive and appropriate for each named executive officer, using their professional experience and judgment. Pay decisions are not made by use of a formulaic approach or benchmark; the Compensation Committee believes that executive pay decisions require consideration of a multitude of relevant factors which may vary from year to year. In making executive compensation decisions, the Compensation Committee generally takes into consideration the factors listed below.

• Company performance and existing business needs.

• Each named executive officer’s individual performance, scope of job function and the critical skill set of the named executive officer to the company’s future performance.

• The need to attract new talent to our executive team and retain existing talent in a highly competitive industry.

• A range of market data reference points, as described in the section titled “—Use of Competitive Market Compensation Data”.

• Recommendations from consultants on compensation policy determinations for the executive officer group.

#### 34Mirum Pharmaceuticals2025 Proxy Statement

#### TABLE OF CONTENTS

#### Executive Compensation

#### 2024 Executive Compensation Program

#### Base Salary
In January 2024, the Committee reviewed the base salaries of the Company’s executive officers, including the named executive officers and increased the salaries as follows:

| Name                 |     | 2023 Base 
 Salary    |     |   |         |     | 2024 Base 
 Salary    |     |   |         |     | Percentage 
 Increase   |      |     |
|:---------------------|:----|:----------|:----|:--|--------:|:----|:----------|:----|:--|--------:|:----|:-----------|-----:|:----|
| Christopher Peetz    |     |           |     | $ | 660,000 |     |           |     | $ | 730,000 |     |